Compare UTMD & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTMD | OABI |
|---|---|---|
| Founded | 1978 | 2012 |
| Country | United States | United States |
| Employees | N/A | 89 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.5M | 237.4M |
| IPO Year | 1994 | N/A |
| Metric | UTMD | OABI |
|---|---|---|
| Price | $63.80 | $2.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 6.4K | ★ 681.6K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $38,520,000.00 | N/A |
| Revenue This Year | N/A | $52.42 |
| Revenue Next Year | N/A | $64.69 |
| P/E Ratio | $78.01 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $52.00 | $1.22 |
| 52 Week High | $71.81 | $2.26 |
| Indicator | UTMD | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 38.48 | 81.15 |
| Support Level | $60.23 | $1.43 |
| Resistance Level | $64.21 | $2.22 |
| Average True Range (ATR) | 1.42 | 0.12 |
| MACD | -0.36 | 0.09 |
| Stochastic Oscillator | 16.39 | 92.31 |
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.